Business Context and Reporting Period
This Form 8-K, dated October 7, 2025, reports the completion of MannKind Corporation's (the "Company") acquisition of scPharmaceuticals Inc. ("scPharma"). The transaction was executed via a tender offer and a subsequent merger under Section 251(h) of the Delaware General Corporation Law, effective October 7, 2025.
Key Financial Metrics and Transaction Details
- Acquisition Price: Approximately $296.5 million in aggregate cash paid to scPharma shareholders.
- Offer Structure: $5.35 per share in cash plus one non-tradable Contingent Value Right (CVR) per share.
- Debt Extinguishment: The Company repaid and extinguished scPharma's existing indebtedness totaling approximately $82.6 million.
- Financing: The Company borrowed $250.0 million in delayed draw term loans under its amended Credit Agreement with Blackstone to fund the acquisition and debt extinguishment.
- Debt Terms: The Blackstone Credit Facility matures on August 6, 2030. Interest is SOFR + 4.75% (subject to a 2% floor), increasing to 5.00% if the indebtedness-to-adjusted EBITDA ratio exceeds 5.00:1.00.
- Share Tender: 39,933,692 shares (73.47%) were validly tendered, with an additional 5,930,025 shares (10.91%) delivered via guaranteed delivery notices.
Material Changes and Contingent Value Rights
The Company entered into a Contingent Value Rights Agreement on October 7, 2025. CVR holders may receive up to $1.00 per CVR based on two milestones:
- Milestone 1 (Regulatory): FDA approval of an SCP-111 injection product. Payments range from $0.25 to $0.75 per CVR depending on whether approval is achieved by September 30, 2026, December 31, 2026, or June 30, 2027.
- Milestone 2 (Commercial): Achievement of at least $110.0 million in worldwide net sales of Injection Products and FUROSCIX Infusors in a trailing 12-month period ending by December 31, 2026. Payments range from $0.10 to $0.25 per CVR based on sales volume up to $120.0 million.
Employee stock options and RSUs were converted into cash (based on the spread between the cash offer and exercise price) and CVRs.
Outlook, Risks, and Management Commentary
- Financial Statements: Unaudited pro forma financial information and financial statements of the acquired business will be filed by amendment within 71 calendar days of this report.
- Risks: There is no assurance that Milestone 1 or Milestone 2 will be achieved by the specified outside dates, meaning CVR payments may be zero.
- Liquidity: The transaction was funded by available cash on hand and new borrowings, increasing the Company's leverage and interest expense obligations.
Investor Verification Checklist
- Verify the final number of shares tendered and the total cash consideration paid, including any adjustments for guaranteed delivery shares.
- Review the upcoming pro forma financial statements (due within 71 days) to assess the combined entity's liquidity and debt service coverage.
- Monitor the progress of SCP-111 toward FDA approval to evaluate the potential value of the CVRs.
- Confirm the Company's ability to meet the $110 million net sales threshold for Milestone 2 by December 31, 2026.
- Assess the impact of the new $250 million debt facility on the Company's future interest coverage ratios and covenant compliance.